• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pipeline

Pipeline

September 21, 2020
Company Drug/Device Medical Condition Status
COVID-19 Trials and Actions
Diffusion Pharmaceuticals trans sodium crocetinate (TSC) hospitalized COVID-19 patients first patients dosed in phase 1b trial
Blade Therapeutics BLD-2660 COVID-19 pneumonia patient enrollment complete in phase 2 trial
Galera Therapeutics avasopasem manganese (GC4419) hospitalized patients who are critically ill with COVID-19 first patients dosed in phase 2 trial
InflaRx IFX-1 severe COVID-19 induced pneumonia initiation of phase 3 portion of phase 2/3 trial
Sorrento Therapeutics COVI-GUARD (STI-1499) hospitalized COVID-19 patients IND approved by the FDA
The Cura Foundation human-cord tissue mesenchymal stromal cells (hCT-MSC) multisystem inflammatory syndrome in children with COVID-19 IND approved by the FDA
Vaxart oral COVID-19 vaccine candidate COVID-19 vaccine IND approved by the FDA
Other Trials and Actions
Enanta Pharmaceuticals EDP-297 non-alcoholic steatohepatitis (NASH) first patients dosed in phase 1 trial
Escient Pharmaceuticals EP547 cholestatic and uremic pruritus initiation of phase 1/1b trial
Bicycle Therapeutics BT8009 advanced solid tumors associated with Nectin-4 expression first patient dosed in phase 1 portion of phase 1/2 trial
Codiak BioSciences exoIL-12 early-stage cutaneous T cell lymphoma first patients dosed in phase 1 trial
CuraSen Therapeutics CST-2032 neurodegenerative disease first patients dosed in phase 1 trial
Immune-Onc Therapeutics IO-202 acute myeloid leukemia with monocytic differentiation and chronic myelomonocytic leukemia first patient dosed in phase 1 trial
Kyorin Pharmaceuticals KRP-R120 interstitial lung diseases first patients dosed in phase 1 trial
Aerpio Pharmaceuticals topical ocular formulation of razuprotafib elevated intraocular pressure associated with open-angle glaucoma or ocular hypertension patient enrollment complete in phase 2 trial
AlzProtect AZP2006 (EZEPROGIND) progressive supranuclear palsy first patients enrolled in phase 2 trial
Anavex Life Sciences ANAVEX 2-73 (blarcamesine) Rett syndrome completion of phase 2 trial
Aura Biosciences suprachoroidal administration of AU-011 primary choroidal melanoma first patient dosed in phase 2 trial
Corcept Therapeutics miricorilant obese patients with schizophrenia and long-standing antipsychotic-induced weight gain first patient enrolled in phase 2 trial
Daiichi Sankyo patritumab deruxtecan (U3-1402) patients with advanced or metastatic colorectal cancer who are resistant, refractory or intolerant to at least two prior lines of systemic therapy first patient dosed in phase 2 trial
Knopp Biosciences dexpramipexole moderate-to-severe eosinophilic asthma patient enrollment complete in phase 2 trial
Roche GDC-9545 plus palbociclib postmenopausal women with ER+ and HER2-negative untreated early breast cancer first patient enrolled in phase 2 trial
Seneca Biopharma NSI-566 chronic ischemic stroke completion of phase 2 trial
VBL Therapeutics VB-111 in combination with nivolumab metastatic colorectal cancer first patients enrolled in phase 2 trial
Gemini Therapeutics GEM103 geographic atrophy secondary to dry AMD first patient enrolled in phase 2a trial
Arcutis Biotherapeutics ARQ-151 (roflumilast cream) plaque psoriasis patient enrollment complete in phase 3 trial
Arena Pharmaceutical etrasimod moderately to severely active ulcerative colitis first patient dosed in phase 3 trial
Caelum Biosciences

Alexion
CAEL-101 AL amyloidosis patients with Mayo stage IIIa or IIIb disease initiation of two phase 3 trials
EpimAb Biotherapeutics EMB-02 solid tumors IND approved by the FDA
Ascentage Pharma APG-115 gastric cancer Orphan Drug designation granted by the FDA
Essa Pharma EPI-7386 metastatic castration-resistant prostate cancer Fast-Track designation granted by the FDA
Plus Therapeutics Rhenium NanoLiposomes glioblastoma Fast-Track designation granted by the FDA
Regeneron Dupixent (dupilumab) patients 12 years and older with eosinophilic esophagitis Breakthrough Therapy designation granted by the FDA
Cycle Pharma Nityr (nitisinone) hereditary tyrosinemia type 1 FDA approved for new dosing regimen
Micron Medical MOVENTIS PNS, percutaneous implantable pulse generator nerve stimulator system chronic peripheral nerve pain approved by the FDA

 

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing